Departments of Pediatrics and Medicine, Center for Vaccine Development, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Naval Medical Research Center, Silver Spring, MD, USA; Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Lancet. 2018 Feb 24;391(10122):801-812. doi: 10.1016/S0140-6736(17)33296-8. Epub 2017 Dec 16.
Shigellosis is a clinical syndrome caused by invasion of the epithelium lining the terminal ileum, colon, and rectum by Shigella species. Although infections occur globally, and in people of all ages, endemic infections among children aged 1-4 years living in low-income and middle-income settings constitute most of the disease burden. The versatile manifestations of these highly contagious organisms range from acute watery diarrhoea to fulminant dysentery characterised by frequent scant bloody stools with fever, prostration, and abdominal cramps. A broad array of uncommon, but often severe, intestinal and extraintestinal complications can occur. Despite marked reductions in mortality during the past three decades, there are roughly 164 000 annual deaths attributable to shigellosis. Intercontinental dissemination of multiresistant shigella strains, facilitated by travellers and men who have sex with men, has prompted new recommendations for antibiotic therapy. Awareness of disease burden and the emerging threats posed by shigella have accelerated interest in development of shigella vaccines, many of which are being tested in clinical trials.
志贺菌病是由志贺氏菌属侵袭回肠末端、结肠和直肠的上皮引起的临床综合征。虽然感染在全球范围内发生,且可发生于各年龄段人群,但在中低收入环境中 1-4 岁儿童中流行的感染构成了大部分疾病负担。这些高度传染性病原体的表现多样,从急性水样腹泻到以频繁少量带血粪便、发热、乏力和腹痛为特征的暴发性痢疾不等。还可能发生一系列罕见但通常严重的肠道和肠道外并发症。尽管在过去三十年中死亡率显著下降,但每年仍有约 164000 人死于志贺菌病。旅行者和男男性行为者促进了耐药性志贺菌菌株的洲际传播,这促使人们对抗生素治疗提出了新的建议。对疾病负担和志贺菌带来的新威胁的认识,加速了人们对志贺菌疫苗的研发兴趣,其中许多疫苗正在临床试验中进行测试。